Grantee: Medical University of South Carolina

Principal Investigator: Nathan Dolloff, Ph.D.

SCRA awarded the Medical University of South Carolina $870,000. MUSC has $397,000 in matching funds for a total of over one million dollars to bring three innovations into the marketplace. They include a recombinant protein cancer vaccine, an antibiotic-eluting implant device, and a burn wound gel. The project will also connect MUSC investigators with companies across the state to create strategic academic-industry collaborations. The College of Charleston, Furman University, and Wofford College are working with MUSC on the projects. The industry partners are Pearl Biologics of Daniel Island, SC, Parimer Scientific (SCRA Member Company) of Easley, SC, and Leukogene Therapeutics (SCRA Member Company), based at MUSC.

“We are excited to work with the SCRA team in pursuit of our common goal to enhance the development of medical innovations in South Carolina. The timing for SCRA’s SACT program is perfect as it complements the launch of several MUSC programs that boost life science innovation and entrepreneurship. These include the Innosphere Ventures Program, CREW entrepreneurship program, launch of the Blue Sky Labs, plans for an Innovation District, and other important initiatives that will be announced shortly. This is an all-around great collaboration and will build on significant momentum in the SC life science sector.” Nate Dolloff, Chief Technology Officer of the Zucker Institute for Innovation Commercialization, at MUSC